VLS - selection of Comments to Shareholders/ market 21 Aug 2017...

VLS - selection of Comments to Shareholders/ market

21 Aug 2017 -

• Profit for half year down 17.5%
• Period of transformational change for the organisation in the first half performance
• Key leaderships positions filled across the business including, CEO Asia, CFO, VLS Head of Marketing
• Management remains confident in its strategy and takes a longer term view around future growth prospects
• Directors provide the following guidance for the 2017 full year;
• Full year revenue guidance of ∼$38m;
• Full year EBIT guidance of $5.0m to $5.5m.

9 Aug 2017

• Appointment of Asian CEO

18May 2017 – AGM

• task of the Board of Directors is to steer the Company’s strategy of long term growth in sales revenue and profitability,
• Our Australian Herbs of Gold brand is now well placed to penetrate the China market as a result of entering into an exclusive arrangement with Jointown Pharmaceutical Group Co Ltd for distribution in China.
• Appointment of Asia CEO - This will be a crucial role in driving the performance for both the established and emerging markets within the region.

13 Oct 2016

• Andrew O’Keefe – Acting MD then MD from 1 Jan 2017.

22 Aug 2016

• China: Whilst regulatory issues continued the Group is exploring business options to enter this markets

12 May 2016

• Build a sustainable business in each country where operations have been established, however remain in their infancy
• Malaysia & Singapore - Identify opportunities to leverage Group’s position into new customer groups